Advances in pharmacotherapy for the treatment of gout

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 4, 2015, Pages 533-546

  Robinson, Philip C ^a,b   Dalbeth, Nicola ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Allopurinol; Febuxostat; Gout; Pegloticase; Probenecid; Urate

Indexed keywords

ALLOPURINOL; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PROBENECID; URATE OXIDASE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; ANTIGOUT AGENT; CANAKINUMAB; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; THIAZOLE DERIVATIVE; URIC ACID;

DISEASE EXACERBATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDICATION; DRUG RESEARCH; GOUT; HUMAN; REVIEW; METABOLISM; PHASE 3 CLINICAL TRIAL (TOPIC);

ADRENAL CORTEX HORMONES; ALLOPURINOL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BENZBROMARONE; CLINICAL TRIALS, PHASE III AS TOPIC; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; POLYETHYLENE GLYCOLS; PROBENECID; THIAZOLES; URATE OXIDASE; URIC ACID;

EID: 84922932046     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.997213     Document Type: Review

References (104)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of Gout and Hyperuricemia in the US General Population. Arthritis Rheum 2011;63(10):3136-41
2. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2014. [Epub ahead of print
3. Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology 2012;51(5):901-9
4. Robinson P, Taylor W, Merriman T. Systematic review of the prevalence of gout and hyperuricemia in Australia. Intern Med J 2012;42(9):997-1007
5. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health 2007;10(4):231-7
6. Dalbeth N, Collis J, Gregory K, et al. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 2007;46(12):1804-7
7. Rome K, Frecklington M, McNair P, et al. Foot pain, impairment, and disability in patients with acute gout flares: a prospective observational study. Arthritis Care Res 2012;64(3):384-8
8. Robinson PC, Horsburgh S. Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 2014;78:245-51
9. Khanna PP, Perez-Ruiz F, Maranian P, et al. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011;50:740-5
10. Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system?. Ann Rheum Dis 2014;73:1598-600
11. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60
12. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012 64:1431-46
13. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24
14. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4
15. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009;48(Suppl 2):ii9-14
16. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. Arthritis Rheum 2007;57:1324-8
17. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5
18. Li Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?. J Rheumatol 2001;28:577-80
19. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-5
20. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007;66:1056-8
21. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007;34:1888-93
22. Stamp LK, Merriman TR, Barclay ML, et al. Impaired response or insufficient dosage?-Examining the potential causes of inadequate response to allopurinol in the treatment of gout. Semin Arthritis Rheum 2014;44(2):170-4
23. Horsburgh S, Norris P, Becket G, et al. Allopurinol use in a New Zealand population: prevalence and adherence. Rheumatol Int 2014;34:963-70
24. Lindsay K, Gow P, Vanderpyl J, et al. The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 2011;17:1-6
25. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012 64:1447-61
26. Murrell GA, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin pharmacokinet 1986;11:343-53
27. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009;11:135-40
28. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7
29. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529-36
30. Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis 2014. [Epub ahead of print
31. Stamp LK. Safety profile of anti-gout agents: an update. Curr Opin Rheumatol 2014;26:162-8
32. Hung SI, Chung WH, Liou LB, et al. HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-9 5801 and allopurinol hypersensitivity syndrome (AHS). In this case-control study of people with AHS and allopurinol controls, HLAB∗ 5801 was present in all 54/54 (100%) of cases and 15% of allopurinol-tolerant individuals, with calculated odds ratio of 580.3
33. Middleton D. Alllele Frequenices 2014. Available from: http://www. allelefrequencies.net [Last accessed 23 October 2014
34. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56
35. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50
36. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8
37. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of uratelowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68:51-6
38. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013;72:826-30
39. Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21
40. Jennings CG, Mackenzie IS, Flynn R, et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum 2014;44(1):25-30
41. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004;23:1111-16
42. Khosravan R, Grabowski BA, Wu JT, et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin pharmacokinet 2006;45:821-41
43. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61
44. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23
45. Gray CL, Walters-Smith NE. Febuxostat for treatment of chronic gout. Am J Health Syst Pharm 2011;68:389-98
46. Simkin PA. New standards for uric acid excretion and evidence for an inducible transporter. Arthritis Rheum 2003;49:735-6
47. Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as uratelowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol 2013;40:872-6
48. Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?. Drug Saf 2008;31:643-65
49. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7
50. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9
51. Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J 2005;118:U1528
52. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55
53. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63
54. Uchida S, Shimada K, Misaka S, et al. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metab Pharmacokinet 2010;25:605-10
55. Richette P, Briere C, Hoenen-Clavert V, et al. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007;34:2093-8
56. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19:34-8
57. Terkeltaub R. Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol 2007;34:1955-8
58. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306:711-20
59. Baraf HS, Becker MA, Gutierrez-Urena SR, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther 2013;15:R137
60. Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther 2014;16:R60
61. Becker MA, Baraf HS, Yood RA, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis 2013;72:1469-74
62. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dosecomparison colchicine study. Arthritis Rheum 2010;62:1060-8
63. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92
64. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606
65. Schumacher HR, Berger MF, Li-Yu J, et al. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 2012;39:1859-66
66. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9
67. Janssens HJ, Janssen M, van De Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a doubleblind, randomised equivalence trial. Lancet 2008;371:1854-60
68. Rainer T, Cheng C, Graham C, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multi-centre, double-blind, randomized, equivalence trial. Emerg Med J 2014;31:781
69. Man CY, Cheung IT, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7
70. Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993;20:111-13
71. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994;21:1325-7
72. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5
73. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasom. Nature 2006;440:237-41
74. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28
75. Ottaviani S, Molto A, Ea HK, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 2013;15:R123
76. Chen K, Fields T, Mancuso CA, et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010;40:210-14
77. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, doubleblind trials and their initial extensions. Ann Rheum Dis 2012;71:1839-48 triamcinolone groups
78. Terkeltaub RA, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013;15:R25
79. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32
80. Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010;32:2386-97
81. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011;70:1264-71
82. Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, doubleblind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012;64:1462-70
83. Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2012;64:876-84
84. Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 2014;41:1703-11
85. Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 2013;52:1285-92
86. Robinson PC, Merriman TR, Herbison P, et al. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. Rheumatology (Oxford) 2013;52:118-26
87. Stamp LK, Barclay ML, O'Donnell JL, et al. Furosemide increases plasma oxypurinol without lowering serum urate-a complex drug interaction: implications for clinical practice. Rheumatology (Oxford) 2012;51:1670-6
88. Knake C, Stamp L, Bahn A. Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment. Biochem Biophys Res Commun 2014;452(1):157-62
89. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086
90. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79
91. Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2014. [Epub ahead of print
92. Goicoechea M, De Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93
93. Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-10
94. Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol 2012;39:1458-64
95. Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/Pglycoprotein inhibitors. Arthritis Rheum 2011;63:2226-37
96. FDA. Information for Healthcare Professionals. New Safety Information for Colchicine (marketed as Colcrys). 2009. Available from: http://www.fda. gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationfor HeathcareProfessionals/ucm174315.htm [Last accessed 20 October 2014
97. Fleischmann R, Kerr B, Yeh LT, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford) 2014;53(12):2167-74
98. Saag KG, Adler S, Bhakta N, et al. Lesinuard, a novel selective uric acid reabsorption inhibitor, in two phase III clinical trial: combination study of lesinuard in allopurinol standard of care inadequete responders (CLEAR 1 and 2). Arthritis Rheumatol 2014;66(S10):L10
99. De Lau LM, Koudstaal PJ, Hofman A, et al. Serum uric acid levels and the risk of Parkinson disease. Ann neurol 2005;58:797-800
100. Euser SM, Hofman A, Westendorp RG, et al. Serum uric acid and cognitive function and dementia. Brain 2009;132:377-82
101. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34
102. Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011;13(2):R39
103. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46
104. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6